Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 65
- Registration Number
- NCT03362931
- Locations
- 🇸🇬
Tan Tock Seng Hospital /ID# 233014, Singapore, Singapore
🇨🇳Buddhist Tzu Chi General Hospital /ID# 232664, Hualien, Taiwan
🇸🇬Nuh Medical Centre /ID# 232905, Singapore, Singapore
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 11
- Registration Number
- NCT03335852
- Locations
- 🇯🇵
Takeuchi Eye Clinic, Taito-ku, Tokyo, Japan
🇯🇵Kimura Eye and Internal Medicine Hospital, Kure, Hiroshima, Japan
🇯🇵Musashi Dream Clinic, Tennouji-ku, Osaka, Japan
Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control
- Conditions
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 84
- Registration Number
- NCT03325673
- Locations
- 🇨🇦
Centre for Contact Lens Research School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Allergan
- Target Recruit Count
- 383
- Registration Number
- NCT03320850
- Locations
- 🇺🇸
Urological Assoc. of South AZ, Tucson, Arizona, United States
🇺🇸Adult and Pediatric Urology, Bridgeport, Connecticut, United States
🇺🇸CT Clinical Research Center/Urologist Specialist, Middlebury, Connecticut, United States
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Allergan
- Registration Number
- NCT03316898
- Locations
- 🇺🇸
Synergy Research Centers, Lemon Grove, California, United States
🇺🇸Collaborative Neuroscience, Long Beach, California, United States
🇺🇸Alliance Research, Long Beach, California, United States
Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 29
- Registration Number
- NCT03302559
- Locations
- 🇺🇸
SkinMedica Clinical Research and Innovation Center, Irvine, California, United States
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 336
- Registration Number
- NCT03285308
- Locations
- 🇺🇸
Digestive Health Specialist of the South East, Dothan, Alabama, United States
🇺🇸Aurora Care Clinic, LLC, Costa Mesa, California, United States
🇺🇸Savin Medical Group LLC, Miami Lakes, Florida, United States
Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 10
- Registration Number
- NCT03274999
- Locations
- 🇬🇧
Ocular Technology Group International, London, United Kingdom
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 91
- Registration Number
- NCT03233438
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 57
- Registration Number
- NCT03226769
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States